BioVaxys Technology (FRA:5LB) Total Inventories : €0.00 Mil (As of Jul. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology Total Inventories?

BioVaxys Technology's total inventories for the quarter that ended in Jul. 2024 was €0.00 Mil. BioVaxys Technology's average total inventories from the quarter that ended in Apr. 2024 to the quarter that ended in Jul. 2024 was €0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioVaxys Technology's Net-Net Working Capital per share for the quarter that ended in Jul. 2024 was €-0.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioVaxys Technology Total Inventories Historical Data

The historical data trend for BioVaxys Technology's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Inventories Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Total Inventories

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

BioVaxys Technology (FRA:5LB) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

BioVaxys Technology's Net-Net Working Capital Per Share for the quarter that ended in Jul. 2024 is

	Net-Net Working Capital Per Share (Q: Jul. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.33	+	0.75 * 0	+	0.5 * 0	-	1.786
-	0	-	0)	/	241.914
=	-0.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioVaxys Technology's Days Inventory for the three months ended in Jul. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jul. 2024 )	/	Cost of Goods Sold (Q: Jul. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioVaxys Technology's Inventory Turnover for the quarter that ended in Jul. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jul. 2024 )	/	Average Total Inventories (Q: Jul. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioVaxys Technology's Inventory to Revenue for the quarter that ended in Jul. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jul. 2024 )	/	Revenue (Q: Jul. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

BioVaxys Technology Total Inventories Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

BVAXF:USA BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines